Hem Securities has come out with a research report on Cipla. The research firm has initiated a buy signal on the stock with a target price of Rs 370 in medium to long term investment horizon expecting an appreciation of about 25% from the current level of Rs 294, in its report dated November 9, 2009.

"With the expectation of 10 to 12% growth in topline along with rich product pipeline for the regulated markets are the key drivers for the growth of the company. Further, tie-ups with 21 players in the USA for marketing 118 ANDAs of which 36 approved and 23 products already launched will help its topline. Also the partnership with Chinese company for launch of biosimilar could be a booster to tap high value market over the medium term. Being the market leader Cipla Ltd. seems to be extremely attractive investment opportunity. Presently, the stock is trading at Rs 294 which is at 22.85 times to its earnings and 5.29 times to its book value of Rs 55.93. Since the stock offers good opportunity, we initiate a buy signal on the stock with a target price of Rs 370 in medium to long term investment horizon expecting an appreciation of about 25% from the current level of Rs 294", says Hem Securities.

Disclaimer: The views and investment tips expressed by investment experts on moneycontrol.com are their own, and not that of the website or its management. Moneycontrol.com advises users to check with certified experts before taking any investment decisions.

To read the full report click on the attachment.........